Research

The Heymach Lab uses an integrative approach of genomic and proteomic analyses of human lung cancer as well as an extensive collection of cell lines and murine models of lung cancer to advance the understanding of lung malignancies. Key lab interests include investigating frequent  drivers of lung cancer such as LKB1 loss, oncogenic KRAS, and EGFR activating mutations. Preclinical studies are designed to identify novel therapeutic strategies as well as approaches to overcome therapeutic resistance.  In addition, the Heymach Lab has considerable effort directed at identifying mechanisms by which lung cancer cells escape immune surveillance and designing treatment regimens to best employ immunotherapy strategies.  Studies conducted in the Heymach lab have a bench to bedside approach as preclinical studies can be validated through connections with vast clinical datasets, and promising finding can be rapidly translated into the clinic.